Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
1994-11-10
pubmed:abstractText
Tay-Sachs disease, the prototype of the GM2 gangliosidoses, is a catastrophic neurodegenerative disorder of infancy. The disease is caused by mutations in the HEXA gene resulting in an absence of the lysosomal enzyme, beta-hexosaminidase A. As a consequence of the enzyme deficiency, GM2 ganglioside accumulates progressively, beginning early in fetal life, to excessive amounts in the central nervous system. Rapid mental and motor deterioration starting in the first year of life leads to death by 2-4 years of age. Through the targeted disruption of the mouse Hexa gene in embryonic stem cells, we have produced mice with biochemical and neuropathologic features of Tay-Sachs disease. The mutant mice displayed < 1% of normal beta-hexosaminidase A activity and accumulated GM2 ganglioside in their central nervous system in an age-dependent manner. The accumulated ganglioside was stored in neurons as membranous cytoplasmic bodies characteristically found in the neurons of Tay-Sachs disease patients. At 3-5 months of age, the mutant mice showed no apparent defects in motor or memory function. These beta-hexosaminidase A-deficient mice should be useful for devising strategies to introduce functional enzyme and genes into the central nervous system. This model may also be valuable for studying the biochemical and pathologic changes occurring during the course of the disease.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-13980699, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-1527584, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-1532255, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-1591000, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-1817024, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-1817025, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-2660260, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-2702490, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-2933632, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-2970846, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-3158659, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-4040927, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-404709, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-4360066, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-6225718, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-637827, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-7047999, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-7959736, http://linkedlifedata.com/resource/pubmed/commentcorrection/7937929-8215983
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
11
pubmed:volume
91
pubmed:geneSymbol
HEXA
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
9975-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.
pubmed:affiliation
Section on Biochemical Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.